

慢性疼痛
レポート③

神経障害性三叉神経痛の症状が脂肪由来幹細胞で緩和した症例報告

E Russell Vickers ,et al.
A preliminary report on stem cell therapy
for neuropathic pain in humans
: Journal of Pain Research 2014;7 255-263




Figure 2 Change in daily dosage requirements of medication.

Notes: (A) gabapentin in the group from pre-treatment stage to completion of the trial at 6 months. At the pre-SVF data point, there were six subjects using gabapentin (mean =1,490 mg; SD 1,160.26; range 600–3,200 mg; total 9,300 mg) and at 6 months, there was a trend for lower analgesic need for gabapentin – one subject discontinued the drug and daily drug consumption reduced in the group (mean =823 mg; SD 713.35; range 400–1,600 mg; total 5,300 mg) ($P=0.053$, Student's *t*-test); (B) change in total daily dosage of amitriptyline in the group from pre-treatment stage to completion of the trial at 6 months. At the pre-SVF data point, there were four subjects using amitriptyline (mean =37 mg; SD 11.97; range 25–50 mg; total 137.5 mg) and at 6 months, all four subjects continued using the drug (mean =25 mg; SD 0; total 100 mg) ($P=0.22$, Student's *t*-test).

Abbreviations: SD, standard deviation; SVF, stromal vascular fraction.